Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Kannalife Sciences in Conjunction With Catalent Pharma Solutions to Test Cannabidiol For Encephalopathy


Studies still on track after surprising new ruling from DEA.

Tweetables from this article:

Tweet:  In March 2016 Kannalife received permission from the DEA to import pharmaceutical-grade cannabidiol

Share this!

September 15, 2016 | by Anne Austin

Kannalife Sciences, an independent pharmaceutical company founded in 2010, focuses primarily on R&D and commercial use of cannabinoid molecules to treat neurodegenerative diseases. In March 2016 Kannalife received permission from the US Drug Enforcement Agency (DEA) to import pharmaceutical-grade cannabidiol (CBD) for feasibility studies to be conducted in conjunction with Catalent Pharma Solutions.

The imported cannabidiol has no psychoactive effect, but is a synthetic white solid, Kannalife CEO Dean Petkanas told BioPharm International. The substance will be used to formulate the company’s specific proprietary product - KLS-13019, a patented cannabidiol-like therapeutic compound.

Successful completion of the feasibility studies paves the way for the company to file an investigational new drug (IND) application for clinical studies in humans. Kannalife will study the product’s ability to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE), which are neurodegenerative conditions. HE is a serious neurological disorder that occurs in patients with liver damage or disease and results in toxins (ammonia) being released into the brain, causing neuro-degeneration; CTE results from traumatic brain injury, or repeated blows to the head – common in participants of high impact contact sports like football.

CDB has shown great promise as a neuroprotectant, with the potential to treat many other neurodegenerative diseases including epilepsy, stroke, Parkinson’s disease, and Alzheimer’s.

“We know that CBD is neuroprotective,” says Dr. Bill Kinney, chief science officer at Kannalife. “We have seen effects in both protecting against cell death and increasing cell viability… We think CBD could protect the neurons from future injury and also help them repair.” This has not gone unnoticed in the sports world – Kannalife was recently featured in Sports Illustrated magazine.

“With CTE, and other injuries to the central nervous system, inflammation plays a very important role in exacerbating the injury,” says Ron Tuma, Ph.D., a member of Kannalife’s Scientific Advisory Board. “So it’s the interaction of cannabinoids with the inflammatory process that gives us the hope that it will have therapeutic benefit.”

Re-classification of CBD was under review in the past year by the DEA amid great expectations that cannabis would be rescheduled – perhaps legalized. Conventional thinking is that Schedule 1 classification (a substance with a high potential for abuse without any medical purpose) hinders funding. But in August came the DEA’s unexpected decision - cannabis will remain a schedule 1 controlled substance.

A company press release asserts, “We commend the DEA and respect their position as the ‘FDA drug approval process is the most appropriate way to assess whether a product derived from marijuana or its constituents is safe and effective and has an accepted medical use.’ According to CEO Dean Petkanas, “This news from the DEA validates our business model and our efforts from our inception.”

Keywords: Neurodegenerative Disease, Catalent Pharma


Share this with your colleagues!

Gilead’s Newest Hepatitis C Drug Gets FDA Approval

July 21, 2017 - Dominant player in the chronic hepatitis C virus (HCV) market Gilead has received US Food and Drug Administration (FDA) approval for its newest treatment, Vosevi.

Featured In: Pharmaceutical News

Detecting Alzheimer’s Biomarkers in the Blood Could Improve Early Diagnosis

July 20, 2017 - In an effort to improve rates of early diagnosis and intervention, researchers at Washington University in St. Louis have developed a blood test that can detect some of the hallmarks of Alzheimer’s disease.

Featured In: Biotech News

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.